Influenza, Human
Conditions
Brief summary
The goal of this clinical trial is to compare ZX-7101A in Chinese Adults patients with uncomplicated influenza. The main questions it aims to answer are: * The efficacy of ZX-7101A in Chinese Adults patients with uncomplicated influenza. * The safety of ZX-7101A in Chinese Adults patients with uncomplicated influenza.
Interventions
DRUGZX-7101A
a drug to treatment influenza in Chinese adults
Sponsors
Nanjing Zenshine Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* ≥18 to ≤64 years of age at the time of signing the ICF. * Patients in the screening period met the following criteria: (1) rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; (2) fever ≥ 37.3℃ (axillary temperature) at screening; if taking antipyretics, axillary temperature ≥ 37.3℃ after taking the drug (more than 4 hours). (3) At least one of flu-related systemic symptoms is moderate or greater in severity: a. muscle or joint pain, b. fatigue, c. headache, d. fever. (4) At least one of the influenza-related respiratory symptoms is moderate or greater in severity: a. nasal congestion, b. sore throat, c. cough. * The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization.
Exclusion criteria
* Patients with influenza virus infection requiring hospitalization. * High-risk population. * Bronchitis, pneumonia, pleural effusion or interstitial disease suspected by a clinician or confirmed by chest imaging \[X-ray (anteroposterior or anteroposterior)/CT\] and judged clinically significant by the investigator at screening. * Patients who have developed acute respiratory tract infection, otitis media, and sinusitis within 2 weeks before screening. * Patients with other infections requiring systemic anti-infective treatment, or blood routine examination at screening: white blood cell count (WBC) \> 10.0 × 109/L. * Patients with purulent sputum or suppurative tonsillitis. * Those who have difficulty in swallowing drugs or have a history of gastrointestinal diseases that seriously affect drug absorption. * Medications against influenza virus within 7 days prior to Screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time to the remission of all influenza symptoms (hours) | from accepting ZX-7101A until the 15 days after the first dosing | Defined as the time from the start of study treatment to the time all flu symptoms are relieved. Symptom relief was defined as all seven influenza symptoms assessed by the subject on the subject diary card(Stuffy nose, sore throat, cough, muscle or joint pain, fatigue, headache, fever or chills/sweating) were 0 (asymptomatic) or 1 (mild); |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 | from accepting ZX-7101A until the 15 days after the first dosing | The Number of Participants with Treatment-Related Adverse Event will be evalated as the change of vital signs, electrocardiogram (P Wave, QRS Complex, QT Interval), physical examination, and Laboratory test compared with the baseline. |
Countries
China
Outcome results
None listed